Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Personalised treatment can help a care team choose among options by using information about a cancer’s biomarkers, molecular features and, in some cases, a patient’s inherited cancer risk. It does not mean there is a bespoke drug for every person: a test may identify a relevant option or clinical trial, but it cannot guarantee that a suitable treatment exists or that it will work.
What personalised cancer care means
Precision medicine, also called personalised medicine, uses information about a person’s cancer and health to inform care. The National Cancer Institute (NCI) describes biomarker testing as an important part of this approach. Targeted therapies act on proteins involved in cancer-cell growth, division or spread, and testing may help clinicians identify treatments more likely to help or avoid ones less likely to do so.
The useful question is not whether a treatment is “personalised” in the abstract, but whether a particular result is relevant to a specific cancer and decision. Results may help guide treatment choices or determine whether a clinical trial is an option. They are considered alongside the cancer’s type and stage, prior treatment, overall health and the patient’s preferences.
Three kinds of information that can shape a decision
| Information | What it describes | How it may inform care |
|---|---|---|
| Tumour biomarker | A feature measured in cancer tissue, such as a protein or a change in how DNA is repaired. | May help identify a treatment that acts on that feature or provide information relevant to trial eligibility. |
| Molecular subtype | A broader classification based on the cancer’s molecular characteristics. | Can help describe groups of cancers that behave differently and may respond differently to treatment. |
| Inherited predisposition | A gene change present in a person’s cells, which may affect their risk of developing certain cancers. | Can inform care decisions and discussions about inherited risk; it is a different question from what a tumour test reveals. |
A tumour test and an inherited-risk test are not interchangeable. A tumour result concerns the cancer being assessed; inherited testing asks whether a genetic predisposition may run through a person’s cells and potentially have implications beyond that tumour. The NCI’s genetics guidance describes inherited cancer predisposition testing as information that may inform care. Which test is appropriate, and how to interpret its result, belongs in a discussion with the clinical team.
Why the cancer type matters
“Gynaecological cancer” covers distinct diseases, including cancers of the ovary, fallopian tube, peritoneum, cervix and endometrium. A biomarker or treatment example in one disease should not be assumed to apply to another. The NCI’s patient guidance illustrates how the role of testing differs by cancer type.
Ovarian, fallopian tube and primary peritoneal cancers
NCI treatment information lists surgery, chemotherapy and targeted therapy among options for ovarian epithelial, fallopian tube and peritoneal cancers. It also distinguishes approaches being studied in clinical trials from treatment options described in patient guidance. A trial treatment is investigational in that context; its presence in research does not establish that it is standard care or suitable for an individual.
Rank #2
- Track important events like birthdays, anniversaries, holidays, and other special occasions so you don’t forget.
- Keep up with activities such as meetings, dates, appointments, and deadlines.
- Organize work projects and tasks to stay on track throughout the year.
- Jot down ideas and keep a running “to do” list of things you want to accomplish.
- Set reminders for yourself to motivate yourself to reach your goals.
Cervical cancer
NCI describes targeted therapy and immunotherapy as treatment approaches for cervical cancer. It reports that pembrolizumab is used for certain patients whose cervical cancer has the biomarker PD-L1. This is an example of a biomarker informing treatment for some patients, not a recommendation for everyone with cervical cancer. Drug indications and guidance can change, so the care team should confirm what applies to a particular case.
Endometrial cancer
The Cancer Genome Atlas identified four molecular subtypes of endometrial cancer in 2013. NCI reports that these subtypes correlate with survival, which makes them useful for understanding differences among groups; that finding does not determine an individual patient’s prognosis.
NCI’s 2024 meeting summary describes mismatch-repair deficiency (dMMR) and microsatellite instability (MSI) as biomarker findings associated with greater sensitivity to immune checkpoint therapy. The summary estimates that approximately 25–35% of endometrial cancer cases have this dMMR/MSI context. That group-level figure does not show whether a specific treatment is appropriate for an individual. NCI also reports that 75–80% of uterine cancers are endometrioid; this describes a cancer type, not a person’s treatment eligibility or outlook.
What a test result can—and cannot—tell you
- It may point to a relevant option. A result can help clinicians consider a treatment or a clinical trial when the finding and the clinical context match.
- It does not guarantee a match. Testing may not find a biomarker linked to an available treatment, and not every finding has a treatment option.
- It does not guarantee response. A biomarker can inform a choice without predicting with certainty how a cancer will respond.
- It does not replace clinical judgement. Test results are one part of decisions that also depend on the cancer, prior care, health and patient preferences.
That distinction matters because a test can be informative even when it does not lead to a new drug choice. It may help rule out an option, clarify the type of cancer, or support a conversation about research studies. The result needs interpretation in its clinical setting rather than as a stand-alone answer.
Rank #4
How to discuss personalisation with a care team
Patients can use a consultation to clarify what a proposed test is intended to answer and what its result might change. Useful questions include:
- Is this test analysing the tumour, inherited risk, or both?
- Which specific treatment decision could the result inform for this cancer type?
- What would a positive, negative or inconclusive result mean in this situation?
- Would the result affect treatment now, or mainly inform trial eligibility or future planning?
- Is the option being discussed established care or under investigation in a clinical trial?
- Who can explain the implications of an inherited-risk result for the patient and, where relevant, their family?
Because treatment indications, guidelines and trial availability change, current options should be confirmed with the oncology team. The NCI materials cited here provide patient-facing examples, not a complete review of every gynaecological cancer subtype or a substitute for current professional guidance.
Quick Recap
Best Value
- [Pink Ribbon and Inspirational Design] This medical logbook centrally organizes all your breast cancer health records, including follow-up records, medication plans, post-operative recovery, and breast-related medical history. Say goodbye to disorganized documents
- [Premium Materials]Features a thick, durable hard cover with robust double-thread binding, built-in category labels, and convenient elastic bands. Every detail has been meticulously designed for both sturdiness and durability, while also ensuring easy everyday browsing and carrying
- [Convenient Design] 6.5 x 8.4 inches, thick hardcover, double-stitched binding, divider labels, elastic band, pen holder. Thick, ink-resistant inner pages, three-section bookmarks, and inspirational coloring pages provide daily encouragement
- [Comprehensive Layout] Divided pages designed specifically for breast cancer patients, with dedicated sections for breast cancer medical records, surgical records, chemotherapy and radiotherapy records, follow-up records, and emergency care records. This allows you to quickly find key medical information during follow-up visits, emergencies, or other unexpected situations
- [Meaningful Health Gift] The pink ribbon theme conveys support and care, making it a meaningful gift for yourself or for friends and family experiencing or overcoming breast cancer. Add a touch of warmth to breast cancer awareness month
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
